Results of a Pilot Point-of-Care (POC) HIV Testing Program using INSTI HIV in an Urban Sexual Health Clinic in Canada Presentation to: 2007 HIV Diagnostics.

Slides:



Advertisements
Similar presentations
HIV Counseling, Testing and Referral (CTR) Services at Boston Medical Center Vanessa J. Sasso, MSW Manager, HIV CTR Program Center for HIV/AIDS Care and.
Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section
HIV Counselling and Testing
Rapid Diagnostic Tests for Syphilis A Preliminary Review of the U. S
Jane Greer Hassle Free Clinic HIV Test Conference June, 2013.
QUALITY CONTROL: INSTI Controls Preparation/SET-UP
Unit 6 Diagnosis & Follow-up of HIV Infection
Rapid HIV Testing and Its Role in Advancing HIV Prevention: 2004 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers.
Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
GENERAL AWARENESS ON HIV/AIDS Presented by: WeHELP In Association with its MEDICAL TEAM.
Rapid HIV Testing: 2005 Update Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Division of HIV/AIDS Prevention.
Integration: Intersection for Reproductive Health and HIV Programs: the Kenyan Experience Family Health International Sponsored Satellite Session World.
Integrating Rapid HIV Testing in Emergency Care Improves HIV Detection Evan M. Cadoff, MD Robert Wood Johnson Medical School New Brunswick, NJ
Simplification, cost-reduction strategies and examples from the field Teri Roberts Diagnostics Advisor Médecins Sans Frontières, Access Campaign 7th.
12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.
An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Increasing Our Reach through Rapid HIV Testing Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and.
Can a second rapid HIV test discriminate false positives as effectively as a Western Blot? The NJ Experience Evan M. Cadoff, MD Robert Wood Johnson Medical.
Counseling Message: Both rapid tests we ran today were preliminary positive. It is likely that you have HIV. We always want to make absolutely sure, though,
Community HIV testing for men who have sex with men (MSM) Will it decrease undiagnosed infection? Jonathan Roberts Liaison Health Adviser Brighton & Sussex.
Senior Health Adviser, 56 Dean Street
Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.
Learning Objectives How to detect HIV antibodies/HIV infection?
HIV Testing CDC power point edited by M. Myers
Shelley Facente, Thomas Knoble, Omar Menendez, Teri Dowling San Francisco Department of Public Health, HIV Prevention Section Kevin Delaney Division of.
Implementing Rapid HIV Testing in New York State Mara San Antonio-Gaddy Director Bureau of Direct Program Operations NYSDOH, AIDS Institute.
HIV Rapid Testing Dr. Kevin Harvey National HIV/AIDS Programme Ministry of Health Jamaica.
HIV Screening and Women’s Health Health Care Education & Training, Inc. Originally developed by: Section 5: Test Options.
Trainer Role Play Module 6 Framing Assessing Prevention counseling Debrief Mod 6 (1 of 3)
Rapid HIV Testing: 2003 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and Prevention.
Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background.
CLINICAL TRIAL OF THE HEMA-STRIP HIV RAPID TEST USING FINGERSTICK BLOOD, WHOLE BLOOD, PLASMA, AND SERUM Niel T. Constantine 1, Dan Bigg 2, Daniel Cohen.
Factors associated with post-operative follow-up after voluntary medical male circumcision in Nyanza Province, Kenya Arbogast Oyanga Monitoring and Evaluation(M&E)
An Approach for a Rapid HIV Antibody Home-Use Oral Fluid Test 1 An Approach for a Rapid HIV Antibody Home-Use Oral Fluid Test OraSure Technologies, Inc.
RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.
The policy development for introducing of the oral fluid based rapid HIV test kit in Thailand Writers in the 2009 Write Workshop (WHO Bulletin)
Monitoring, supervision and quality control IDSP training module for state and district surveillance officers Module 11.
HIV diagnosis (general) ImmunoassaysNAT (PCR)
Acute HIV Follow-Up in NC Presented by Muhammad “Maxi” Mackalo, DIS.
CTS HIV Test Request Forms Training. Overview Introduction Introduction Explore new form Explore new form Practice Practice.
E001372A 1 ARC Experience with Indeterminate Blood Donors Susan L. Stramer, Ph.D. National Confirmatory Testing Laboratory American Red Cross.
Trinity Biotech Fingerstick whole blood sample for HIV OTC test Presented by; Fiona Campbell.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Introduction to OraQuick Rapid HIV Testing William F. Ryan Community Health Center School Based Health Program.
Research Meets Practice and Beyond: Clinical Implementation of HIV Rapid Testing Dissemination Workshop October, 2009 Louise Haynes, MSW Beverly Holmes,
Compatibility Testing practical NO 4 Dr: Dalia Kamal Eldien.
RAPID HIV TESTING OraQuick ADVANCE HIV 1/2
Blood Grouping Slide & Tube Methods
RETROVIRIDAE GENUS: ONCOVIRUS: HTLV-1 and HTLV-2 SPUMAVIRUS LENTIVIRUS: HIV-1 and HIV-2.
IPC INFECTION PREVENTION & CONTROL PROGRAM Improving post-exposure prophylaxis (PEP) reporting and documentation: Experiences from Iringa pilot Amal Ally.
Provider Initiated HIV Counseling and Testing Unit 2: Introduction and Rational for PIHCT.
Performing HIV Rapid Tests
1 Module 2: HIV Counseling and Testing for PMTCT Ministry of Health/HAPCO, Ethiopia.
Matilu Mwau, M.D., MTM, D.Phil(Oxon)
Evaluation of Alere q HIV-1/2 VL Plasma
California Clinical Laboratory Association
Provider Initiated HIV Counseling and Testing
The Impact of Routine Counseling and Testing with an Opt-Out Strategy Compared to Voluntary Counseling and Testing in the Implementation of PMTCT Services.
Do Patients adherent on PrEP exposed to HIV have seroconversion symptoms & falsely reactive HIV tests? Mark Roche1, Elaney Youssef1, Yvonne Gilleece¹,
Coombs test practical(3)
INTEGRATING HIV AND HCV TESTING.
Effect of POC CD4 testing at HIV diagnosis on attrition prior to ART initiation among youth in Khayelitsha, South Africa Pre-treatment losses to care remains.
Quality System Considerations for Over-The-Counter HIV Testing
Towards the last 90% of the 90:90:90 strategy: A review of viral suppression rates in a HIV program in Central and Eastern Kenya Dr Moses Kitheka,
Practical Blood Bank Lab 1 ABO Grouping.
A CASE SERIES OF DISCORDANT LABORATORY RESULTS WITH RAPID HIV TESTING
Practical Blood Bank Lab 1 ABO Grouping.
TRACE INITIATIVE: Data Collection Tools and Forms
About bioLytical Laboratories
Presentation transcript:

Results of a Pilot Point-of-Care (POC) HIV Testing Program using INSTI HIV in an Urban Sexual Health Clinic in Canada Presentation to: 2007 HIV Diagnostics Conference Atlanta, December 5-7, 2007

2 Hassle Free Clinic, Toronto Community-based inner city sexual health clinic (1973) Funded by City of Toronto, Ontario Ministry of Health and Long-term Care (MOHLTC) and donations Approximately 18,000 client visits per year (non HIV) Offers anonymous HIV testing (since 1985) Legislated in 1992, guidelines developed by MOH Voluntary testing, counseling and reporting system >5000 tests per year First Canadian clinic to offer HIV Point of Care testing Male (70%) Female (30%)

3 Rationale for HIV POC testing Uptake and access – high client and provider satisfaction Requires only one appointment for pre and post-test counseling for non-reactive results (>98%) Ensures continuity with client Better reinforcement of harm reduction strategies Increased acceptance of negative results Easier to deliver preliminary reactive results Follow-up appointment for confirmatory results May require additional support during wait period If high risk, clinic begins referral process before confirmatory Increased clinic capacity (25% more clients), better workflow

4 INSTI HIV Test Produced by bioLytical Laboratories Inc., Richmond, BC 2 years of Canadian clinical trials, 16,000 tests Licensed as Class IV Medical Device by Health Canada, 2005 CE Marked USAID PEPFAR waiver listed Package insert performance characteristics Sensitivity (fingerstick) 99.6% [CI 98.9 – 99.5%] Specificity (fingerstick) 99.3% [CI 98.9 – 99.5%]

5 INSTI Test System Human IgG IgG capture/ blue labeled IgG capture Control Spot Test Spot IgG capture/ blue labeled Anti-HIV 1/2 HIV 1/2 Antigens

6

7 INSTI Procedure:

8 INSTI Procedure… Add Developer (2)

9 INSTI Procedure… Add Clarifying Solution (3)

10 NON-REACTIVE: One blue dot, clearly discernible above any background tint on the membrane. This is the IgG Control Spot: shows test has been performed correctly and sample has been added. The control is located towards the top of the read frame, furthest from the plastic tab on the Membrane Unit. No reaction should be visible at the test spot, located below the control. This result indicates antibodies to HIV-1/HIV-2 were not detected. INSTI Interpretation CONTROL TAB

11 INSTI Interpretation…2 REACTIVE: Two blue dots discernible above any background tint indicate possible presence of HIV-1/HIV-2 antibodies. One dot may be darker than the other. A sample giving this pattern is considered a preliminary reactive. Following a reactive rapid test result, a venous blood sample must be drawn for laboratory-based confirmatory testing. TEST CONTROL TAB CONTROL TEST TAB TEST CONTROL TAB

12 TAB TAB TEST A.There is no dot on the membrane INVALID results : B.The test dot appears without the control dot Recommendation: INVALID tests with finger- stick blood samples in POC settings should be repeated with a fresh sample using a new membrane unit, kit components, and support materials. INSTI Interpretation…3

13 TAB TEST CONTROL The test is INDETERMINATE if a faint background ring appears on the test area. Following an indeterminate test result, a venous blood sample must be drawn in an EDTA collection tube (for whole blood or plasma) or red-top tube (for serum), and forwarded to a laboratory for HIV confirmatory testing. INDETERMINATE: INSTI Interpretation…4

14

15 Objective To evaluate the efficacy of HIV POC testing at Hassle Free Clinic To set standards of care for HIV POC testing To monitor client uptake and satisfaction To evaluate provider satisfaction

16 Methods Clients attending HFC for anonymous HIV testing were offered routine lab based or POC testing during pre-test counseling Routine HIV testing was performed by the Central Public Health Laboratory (CPHL) POC testing was done using INSTI HIV POC Negative clients received post-test counseling POC Reactive clients were counseled and offered lab-based confirmatory testing Confirmatory testing (EIA, p24, WB) was done STAT by CPHL Final post-test counseling and referrals in 1-2 weeks

17 Results Between May 15, 2006 and September 30, clients attended HFC for HIV anonymous testing 4721 Male (53% MSM, <1% High Risk Heterosexual (HRH)) 1824 Female ( 8% HRH, <1% IDU)

18 Results – Proportion choosing POC Males – 96.5% (4560/4721) Females – 87.1% (1615/1824) Overall – 94.3% (6175/6545)

19 Results – POC Testing Males N=4560 Females N=1615 Negative Reactive787 Indeterminate102

20 Results – Follow-up testing Males – 78 Reactive + 10 Indeterminate = accepted confirmatory testing 7 declined follow-up testing 5 had a previous HIV diagnosis 1 opted to go to primary care physician for confirmatory 1 declined confirmatory Females – 7 Reactive + 2 Indeterminate = 9 8 accepted confirmatory testing 1 declined follow-up testing 1 had a previous HIV diagnosis

21 Results – Confirmatory Testing for POC Reactive Clients Males* N= 81 Females N= 8 HIV Positive716 HIV Ind3 (all HIV +)0 HIV Negative72

22 Conclusions - INSTI Performance Specificity 6079/6087 x 100 = 99.85% [CI ] Positive Predictive Value 80/89 x 100 = 89.89%

23 Conclusions Based on HFC experience and INSTI HIV performance, the MOH is expanding rapid HIV POC testing to 60 anonymous HIV and sexual health clinics in Ontario Implementation includes new counseling guidelines, training for providers, rigorous quality assurance policies and procedures including kit controls and external quality assessment, and a system to collect epi data on all testers. Anticipated volume – 60,000 tests per year

24 Acknowledgements Hassle Free Clinic Jane Greer, Leo Mitterni, Craig Stephen, Amy Lin AIDS Bureau, Ontario Ministry of Health and Long-term Care Frank McGee Ken English Public Health Laboratories Carol Swantee Ontario HIV Treatment Network Carol Major McMaster University Bethany Henrick